Abstract
The in vivo properties of a series of 2-arylindole NK(1) antagonists have been improved, by modification of the amide substituent. The 1-(2-methoxyphenyl)piperazine amide was identified as a major area of metabolism in the lead compound 1. Replacement of this amine moiety by a 4-benzyl-4-hydroxypiperidine resulted in a compound 18 with reduced clearance and improved central duration of action.
MeSH terms
-
Administration, Oral
-
Amides / chemistry*
-
Animals
-
Biological Availability
-
Cricetinae
-
Drug Evaluation, Preclinical
-
Indoles / pharmacokinetics*
-
Inhibitory Concentration 50
-
Metabolic Clearance Rate
-
Neurokinin A / antagonists & inhibitors*
-
Piperazines / chemistry
-
Rats
-
Structure-Activity Relationship
Substances
-
1-(2-methoxyphenyl)piperazine amide
-
Amides
-
Indoles
-
Piperazines
-
Neurokinin A